ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. The company's primary product candidate is neffy, a needle-free intranasal delivery system for epinephrine. Neffy is designed for the emergency treatment of Type I allergic reactions, offering an alternative to traditional auto-injectors. The company operates in the United States and globally, aiming to address the unmet medical need for a non-invasive, easy-to-administer epinephrine option. ARS Pharmaceuticals was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol SPRY. The company's financials are reported in US Dollars (USD), reflecting its primary operations in the United States. As a Nasdaq-listed company, it is subject to the exchange's listing requirements and regulatory oversight. Investors trading SPRY shares typically use USD, and the stock's performance is influenced by factors affecting the US healthcare and biotechnology sectors.

ARS Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of therapies for severe allergic reactions. The company's work involves innovative drug delivery technologies, such as its intranasal epinephrine product neffy. Biotechnology firms like ARS Pharmaceuticals often engage in lengthy clinical trials and regulatory processes before bringing products to market. The company's industry classification reflects its core activities in developing novel treatments for life-threatening conditions.

ARS Pharmaceuticals is headquartered in San Diego, California, United States. The company serves both the US and global markets, as indicated in its business description. Its product neffy is intended for emergency treatment of Type I allergic reactions, including anaphylaxis, which affects patients worldwide. While the company's primary operations are in the US, it aims to commercialize its treatments internationally. The San Diego location places it within a major biotechnology hub, providing access to talent and research resources.

ARS Pharmaceuticals' main product is neffy, a needle-free intranasal delivery system for epinephrine. Neffy is designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Unlike traditional epinephrine auto-injectors that require a needle injection, neffy delivers the drug via a nasal spray, which may reduce patient anxiety and improve ease of use. The product is intended to provide rapid absorption of epinephrine through the nasal mucosa, offering a non-invasive alternative. The company is focused on gaining regulatory approval and commercializing neffy in the US and globally.